The main aim of Professor Ingelsson’s research is to increase our understanding of the neurotoxic mechanisms in the Alzheimer’s disease and Parkinson’s disease brain and to utilize this knowledge to develop novel therapeutic and diagnostic applications. His research thus has a pronounced translational character where immunotherapy and gene therapy approaches against pathogenic protein species are being evaluated on cell and animal models. His group has spearheaded the development of an immunotherapy protocol against Parkinson’s disease, which has been proven to successfully reduce alpha-synuclein pathology on cell and pre-clinical models. This therapeutic strategy has resulted in a humanized antibody, which is undergoing pre-clinical development. Moreover, the group has developed a CRISPR/Cas9-based protocol for treatment against APP in a familial form of Alzheimer’s disease. This therapy has also been successfully evaluated on cell and pre-clinical models.